BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35865478)

  • 1. Circulating Tumor DNA Characteristics Based on Next Generation Sequencing and Its Correlation With Clinical Parameters in Patients With Lymphoma.
    Wu XB; Hou SL; Zhang QH; Jia N; Hou M; Shui W
    Front Oncol; 2022; 12():901547. PubMed ID: 35865478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA.
    Sun P; Chen C; Xia Y; Wang Y; Liu PP; Bi XW; Shao YW; Ou QX; Wu X; Yang H; Nie M; Zhang XW; Li ZM; Jiang WQ
    J Cancer; 2019; 10(2):323-331. PubMed ID: 30719126
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring.
    Esmeray E; Küçük C
    Turk J Biol; 2020; 44(1):1-14. PubMed ID: 32123491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
    Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
    Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
    Zhang W; Wang W; Han X; Gan Y; Qian L; Zhang Y; Zhang C; Wang Y; Guan Y; Yang L; Zhou D
    Int J Lab Hematol; 2021 Oct; 43(5):1041-1049. PubMed ID: 33734593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA in Hodgkin lymphoma.
    Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
    Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinheiro M; Santos C; Pinto C; Escudeiro C; Bartosch C; Santos R; Brandão A; Silva J; Teixeira MR
    Front Oncol; 2021; 11():754094. PubMed ID: 34660321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
    Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
    Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
    Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
    Front Oncol; 2022; 12():830816. PubMed ID: 35280779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.
    Yang H; Zhang J; Zhang L; Wen X; Luo Y; Yao D; Cheng T; Cheng H; Wang H; Lou F; Guo J; Liang X; Cao S; Chen J
    Oncol Lett; 2019 Nov; 18(5):4762-4770. PubMed ID: 31611986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.